COPD Exacerbations: Warning Signs, Treatment, and Prevention

Intro

An exacerbation of COPD (chronic obstructive pulmonary disease) is an acute and sustained worsening of respiratory symptoms — breathlessness, cough, and sputum production — that goes beyond a person’s normal day-to-day variation and requires a change in regular treatment. Exacerbations are often called flares.

For people with COPD, exacerbations are one of the most significant events in the course of the disease. They are a leading cause of hospitalisation and emergency department visits in people over 40, are associated with accelerated decline in lung function, and account for a substantial proportion of COPD-related deaths. Yet most people with COPD are not well-prepared to recognise or respond to them promptly.

This guide covers how to recognise a COPD exacerbation, when to seek urgent care, what treatment involves, and how to reduce future flares.

Key Points

COPD exacerbations are acute worsening of breathlessness, cough, and/or sputum that differs clearly from baseline and lasts at least 2 days.
Most are triggered by respiratory tract infections (viral or bacterial); air pollution and cold air are also triggers.
Early treatment — within 24–48 hours of symptom onset — produces better outcomes.
Treatment combines increased bronchodilator use, a short course of oral corticosteroids, and antibiotics when sputum is purulent.
Severe exacerbations require hospital care; oxygen must be titrated carefully (target SpO2 88–92%) to avoid CO2 retention.
Non-invasive ventilation (NIV) is the treatment of choice for hypercapnic respiratory failure.
Exacerbations accelerate lung function decline and increase mortality — prevention is as important as treatment.
Frequent exacerbations (≥2 per year) are the single strongest predictor of future exacerbations.

Background

What is COPD?

COPD is a chronic, progressive lung condition characterised by persistent airflow obstruction that is not fully reversible. It encompasses emphysema (destruction of alveolar walls) and chronic bronchitis (chronic airway inflammation with excess mucus). Almost all COPD is caused by smoking, though occupational dust and fume exposure and indoor air pollution (biomass burning) contribute.

COPD affects an estimated 10% of people over 40 worldwide; it is significantly under-diagnosed. The airflow obstruction is characterised by the FEV1/FVC ratio (<0.7) on spirometry.

For a full introduction to COPD, see COPD: Symptoms, Diagnosis, and Management.

Why exacerbations matter

Each exacerbation:

Causes temporary but significant worsening of quality of life and functional capacity
May not fully recover to pre-exacerbation baseline (particularly severe episodes)
Accelerates long-term decline in lung function
Carries hospitalisation mortality of 4–10%; ICU admission carries ~25% mortality
Is associated with increased risk of cardiovascular events (myocardial infarction, atrial fibrillation) in the days to weeks following

People who experience frequent exacerbations (≥2/year) form a distinct phenotype with a worse prognosis and require more aggressive prevention strategies.

Triggers

COPD exacerbations are triggered in approximately:

~50% by viral respiratory tract infections (rhinovirus, influenza, RSV, coronavirus, parainfluenza)
~25% by bacterial infections (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas in severe COPD)
~10% by air pollution (particulate matter, ozone, nitrogen dioxide)
~15% by other or unknown factors (cold air, allergens, medication non-adherence, cardiac events)

Viral and bacterial coinfection is common and tends to produce more severe exacerbations.

Recognising an Exacerbation

Symptoms

A COPD exacerbation involves two or more of the following, sustained for at least 2 days:

Increased breathlessness beyond your usual level
Worsened cough — more frequent or more severe
Change in sputum — increased volume, thickness, or purulence (green/yellow)

Additional symptoms may include chest tightness, wheeze, reduced exercise tolerance, fever (if infection), and general malaise.

Severity classification (GOLD)

Severity	Features	Treatment setting
Mild	Increased use of reliever inhaler only	Self-managed at home
Moderate	Requires oral corticosteroids and/or antibiotics	GP or urgent care
Severe	Requires hospital admission	Emergency department
Very severe	Life-threatening; requires ICU or NIV	ICU/HDU

Red flags — seek emergency care immediately

Breathlessness at rest or rapidly worsening
Unable to complete a sentence
Lips, fingernails, or skin turning blue or grey (cyanosis)
Confusion, drowsiness, or altered consciousness
Respiratory rate >25 breaths per minute
Heart rate >110 beats per minute at rest
Reliever inhaler providing no relief

Treatment

At home (mild exacerbation)

Increase reliever bronchodilator — use short-acting beta2 agonist (SABA, e.g., salbutamol) and/or short-acting anticholinergic (SAAC, e.g., ipratropium) more frequently. Use a spacer if using a metered-dose inhaler.
Start prednisolone — if you have a rescue pack prescribed by your doctor (typically prednisolone 30mg for 5 days). Starting steroids early reduces recovery time.
Start antibiotics — if you have purulent (green/yellow) sputum and antibiotics are included in your rescue pack.
Follow your COPD action plan — written plans specifying when to use each rescue medication reduce hospitalisation rates and improve outcomes.

GP/urgent care setting (moderate exacerbation)

Short-acting bronchodilators — repeated doses via nebuliser or high-dose inhaler
Oral prednisolone 30–40mg for 5 days
Antibiotics (if purulent sputum): amoxicillin, doxycycline, or clarithromycin are first-line; choice depends on previous sputum cultures and local resistance patterns
Pulse oximetry assessment — oxygen if SpO2 <88–92% (see below)

Hospital management (severe exacerbation)

Oxygen therapy — one of the most important and nuanced aspects of COPD exacerbation management. Unlike most acute illnesses, people with COPD (particularly those with chronic CO2 retention) must receive controlled oxygen at target SpO2 of 88–92%. Over-oxygenation can worsen CO2 retention by suppressing the hypoxic respiratory drive. Oxygen is given via Venturi mask at specified percentages — never high-flow oxygen uncontrolled.

Bronchodilators — nebulised salbutamol and ipratropium, driven by air (not oxygen where possible) to avoid over-oxygenation.

Corticosteroids — IV or oral prednisolone (equivalent dose); 5-day courses are as effective as longer courses and have fewer side effects.

Antibiotics — as above; IV if unable to take oral, or in severe sepsis. Sputum cultures guide targeted therapy.

Non-invasive ventilation (NIV / BiPAP) — the treatment of choice for hypercapnic respiratory failure (elevated CO2, pH <7.35) — a potentially life-saving intervention that avoids the need for intubation in many patients. NIV provides positive pressure support through a mask, reducing the work of breathing and improving CO2 clearance.

Invasive mechanical ventilation — required when NIV fails or is contraindicated. Decisions about escalation to ICU should be made in advance with the patient where possible, particularly in severe or end-stage COPD.

Additional hospital considerations

VTE prophylaxis (immobility increases DVT risk)
Monitoring for cardiac complications (atrial fibrillation, acute coronary syndrome)
Nutritional support (poor nutrition is common in severe COPD)
Early involvement of physiotherapy (airway clearance, exercise)
Discharge planning: rescue medication, follow-up within 2 weeks, review of maintenance therapy

Prevention

Preventing exacerbations is the most impactful aspect of COPD management.

Smoking cessation

Stopping smoking is the single most effective intervention in COPD — it slows disease progression, reduces exacerbation frequency, and is the only intervention proven to reduce mortality in COPD.

Vaccinations

Annual influenza vaccination — reduces exacerbation frequency significantly; strongly recommended for all people with COPD
Pneumococcal vaccination (PCV20 or PPSV23) — reduces bacterial pneumonia risk
COVID-19 vaccination — COVID-19 is a major trigger for severe COPD exacerbations
Pertussis (whooping cough) and RSV vaccination — increasingly recommended for older adults with COPD

Maintenance inhaler therapy

Consistent use of maintenance inhalers substantially reduces exacerbation frequency:

Long-acting muscarinic antagonists (LAMA, e.g., tiotropium) — reduce exacerbation risk; often first-line
Long-acting beta2 agonists (LABA, e.g., salmeterol, indacaterol) — bronchodilation and inflammation reduction
Inhaled corticosteroids (ICS) — added for frequent exacerbators or those with eosinophilic inflammation; combined LAMA/LABA/ICS triples (e.g., fluticasone/umeclidinium/vilanterol) are highly effective in reducing exacerbations in appropriate patients
Roflumilast — oral PDE4 inhibitor; for severe COPD with chronic bronchitis phenotype and frequent exacerbations
Azithromycin — long-term low-dose macrolide antibiotic; reduces exacerbation frequency in selected patients (frequent exacerbators, non-smokers) but requires monitoring for hearing loss and cardiac risks

Pulmonary rehabilitation

Pulmonary rehabilitation — a structured programme of supervised exercise, education, and self-management support — is one of the most evidence-based interventions in COPD. It reduces exacerbation frequency, hospitalisation rates, and improves quality of life and exercise capacity. It is recommended for anyone who has had a recent exacerbation or has significant functional limitation.

COPD action plan

A personalised written action plan helps people recognise early exacerbation signs and start treatment promptly. Action plans specifying when to start rescue steroids and antibiotics, and when to seek emergency care, reduce hospitalisation rates and improve outcomes.

Avoiding triggers

Air quality alerts — reduce outdoor activity during high-pollution days
Seasonal precautions — avoid cold air exposure; cover the mouth and nose in very cold weather
Infection avoidance — handwashing, avoiding contact with people with respiratory infections
Indoor air quality — avoid exposure to smoke, dust, and fumes at home

Risks, Benefits, and Prognosis

COPD exacerbations are one of the most common causes of hospitalisation and death in people over 65. Key facts:

After a hospitalised exacerbation, the 30-day mortality is approximately 5–10%.
One-year mortality after hospitalisation for a COPD exacerbation exceeds 20% in older adults with severe disease.
Each exacerbation accelerates the long-term decline in FEV1 beyond the natural trajectory.
People who receive pulmonary rehabilitation after a hospitalised exacerbation have significantly better survival and fewer re-admissions.
Early community-based follow-up (within 2 weeks) after hospital discharge reduces readmission rates.

FAQ

Q: Can I avoid hospital if I have an exacerbation? A: Many mild-to-moderate exacerbations can be managed at home with a rescue pack (corticosteroids, antibiotics, increased bronchodilators) and close monitoring. Hospital-at-home or early supported discharge programmes can also manage some patients safely outside hospital. The key is to recognise warning signs early and have a clear action plan — and to go to hospital if red flag symptoms appear.

Q: What is the difference between a COPD exacerbation and a COPD attack? A: The terms are often used interchangeably. Clinically, “exacerbation” is the preferred medical term — it specifically means a sustained acute worsening that requires a change in treatment, distinct from brief fluctuations throughout the day.

Q: How long does it take to recover from a COPD flare? A: Most people recover within 2–4 weeks for mild-to-moderate exacerbations. Severe exacerbations requiring hospitalisation may take longer; some people do not return to their pre-exacerbation baseline, particularly after repeated severe episodes. Pulmonary rehabilitation begun after the acute phase helps recovery.

Q: Should I keep rescue medications at home? A: Yes, if your respiratory team has prescribed a rescue pack. Having prednisolone and antibiotics at home — with a clear action plan for when to use them — reduces delay in starting treatment. Studies consistently show that early treatment (within 24–48 hours of symptoms starting) leads to shorter and less severe episodes. Ask your GP or respiratory nurse if you do not have a rescue pack.

Q: Can surgery help severe COPD? A: For a small subset of people with severe emphysema, lung volume reduction surgery (LVRS) or bronchoscopic lung volume reduction (endobronchial valves) can improve symptoms and lung function. Lung transplantation is considered for end-stage COPD in selected patients. These are specialist decisions made in tertiary centres.